Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentPriority HealthPolicy N/A

    Priority Health Medicare 2026 Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 formulary for Priority Health Medicare describing covered Part D drugs, coverage rules (prior authorization, step therapy, quantity limits), and how members and prescribers can request exceptions or transition supplies. It affects Priority Health Medicare members and network providers who prescribe or dispense prescription drugs under the plan.

    Policy Summary
    PayerPriority Health Medicare
    Policy2026 Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from Priority Health Medicare before filling drugs designated 'PA' to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026formulary year
    May 1effective
    72 hrsstandard decision
    24 hrsexpedited decision
    30 daystransition supply

    Formulary Coverage and General Conditions

    Formulary Coverage and General Conditions

    Covered drugs and general member/payment rules for the Priority Health Medicare formulary. This section explains what the formulary is, when drugs listed are covered, and common coverage controls and member rights (prior authorization, quantity limits, step therapy, exceptions, and transition supplies).

    ALL of the following

    • Priority Health Medicare will generally cover drugs listed on the formulary when the drug is medically necessary, the prescription is filled at a Priority Health Medicare network pharmacy, and other plan rules are followed.

      See Evidence of Coverage for details.

    • Some covered drugs have additional requirements or limits: Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST). If PA is required, approval must be obtained before the drug is filled or the plan may not cover it.

      Members and prescribers can find PA and ST details on the formulary and plan website.

    • Quantity limits specify the amount the plan will cover for a given time period (for example, 30 tablets of XARELTO 10 mg per prescription).
    Policy Summary
    PayerPriority Health Medicare
    Policy2026 Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from Priority Health Medicare before filling drugs designated 'PA' to avoid coverage denial.
    SourceLink
    On This Page
    Formulary Coverage and General ConditionsFormulary Entries and Coding / Drug ListsPrescriber Requirements, Prior Authorization, and DocumentationStep Therapy Rules and ReferencesQuantity Limits (QL) by Drug / ExamplesHome Infusion, Part B vs Part D, and Benefit RoutingAbbreviations, Tier Legend, and DefinitionsPolicy Background and Scope

    Limits may be expressed as EA, ML, GM per days supply.

  1. Step therapy requires trying one or more preferred drugs before the plan will cover an alternative drug. If the required drug(s) do not work or cause harm, the plan may approve coverage of the alternative drug.

    Prior authorization requests should include prescriber rationale and supporting clinical information.

  2. Members or prescribers may request exceptions: formulary (coverage of a non‑formulary drug), waiver of a coverage restriction (PA, ST, QL), or tiering exceptions to lower cost‑sharing (not applicable for specialty tier).

    Generally, requests are decided within 72 hours; expedited requests when waiting could seriously harm the member must be decided within 24 hours.

  3. Excluded Drugs (ED) are drugs not normally covered in a Medicare prescription drug plan; amounts paid do not count toward total drug costs and extra help does not apply for ED drugs. Only specific Priority Medicare plans may offer coverage for ED drugs.

    See formulary key for ED definition.

  4. Coverage information for specific drugs (tier and requirement flags) is listed in the formulary; abbreviations and the formulary update date appear in the formulary header.
  5. Transition Supplies: when you are a new or continuing member, Priority Health Medicare will provide a temporary supply while coverage decisions or exceptions are pursued. For most situations the plan will cover a temporary 30-day supply; for long‑term care residents or limited access situations beyond the first 90 days, a 31-day emergency supply may be provided. Members experiencing a level-of-care change will receive at least a 30-day transition supply of medication unless the prescription is written for fewer days.

    If coverage is not approved after the temporary supply, the plan will not pay for additional fills beyond the transition supply.

  6. Formulary Entries and Coding / Drug Lists

    Formulary drug entries (partial list)mixed
    cefprozilcefprozil — Tier 2
    ceftaroline fosamilceftaroline fosamil — Tier 4
    ceftazidime injection solution reconstituted 1 gm, 6 gmceftazidime — Tier 4; Requirements/Limits = HI
    ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mgceftriaxone sodium — Tier 4; Requirements/Limits = HI
    cefuroxime axetil oral tabletcefuroxime axetil — Tier 2
    cephalexin oral capsule 250 mg, 500 mgcephalexin — Tier 2
    amoxicillin (various oral forms)amoxicillin — Tier 2
    amoxicillin-pot clavulanate ERamoxicillin-pot clavulanate ER — Tier 4
    ampicillin sodium injection solution reconstituted 1 gmampicillin — Tier 4; Requirements/Limits = HI
    ampicillin-sulbactam sodium injection solution reconstituted 3 (2-1) gmampicillin-sulbactam — Tier 4; Requirements/Limits = HI
    1–10 of 19
    1/2
    Anticonvulsants and specialty agentsmixed
    brivaracetam oral solution/tablet (BRIVIACT)Tier 5; Requirements/Limits = PA; QL (600 ML per 30 days for solution; 60 EA per 30 days for tablet)
    EPIDIOLEXTier 5; Requirements/Limits = PA; QL (500 ML per 30 days)
    perampanel oral suspension/tabletTier 5 (some strengths); Requirements/Limits = PA; QL (varies; e.g., 680 ML per 28 days for suspension; 30 EA per 30 days for tablets)
    levetiracetam (various forms)tiers vary; some disintegrating tablets Tier 4 with PA; QL (60-90 EA per 30 days)
    topiramate, valproic acid, lamotrigine, levetiracetamvarious tiers with occasional QL/PA as listed
    XCOPRI (cenobamate) various strengthsTier 5; Requirements/Limits = PA; QL (varies e.g., 56 EA per 28/30 days depending on pack)
    CNS / dementia / antidepressant agentsmixed
    donepezil HCl oral tablet 5 mg, 10 mg, 23 mgdonepezil — Tiers 1-4 depending on strength; QL for several strengths (e.g., 60 EA/30 days for 10 mg; 30 EA/30 days for 5 mg)
    rivastigmineTier 4 (some forms); Requirements/Limits = QL (30 EA/30 days or 60 EA/30 days for tartrate forms)
    memantine HCl (various forms)tiers 2-4; QL specified for several formulations (e.g., 300 ML/30 days for solution; 49 EA/28 days for combination pack)
    AUVELITY, EXXUA, ZURZUVAE, EMSAMvarious antidepressant agents listed as Tier 5 with PA and/or QL for certain products (e.g., AUVELITY PA; QL 60 EA per 30 days; EXXUA PA; QL 30 EA per 30 days)
    Formulary drug entries (no billing codes provided)mixed
    N/AThis formulary segment does not list CPT/HCPCS/ICD-10/NDC codes; only drug names with tier and requirements are present.
    Selected drug entries with QL examplesmixed
    PAXLOVID (150/100)PAXLOVID (150/100) QL (40 EA per 180 days)
    PAXLOVID (300/100 & 150/100)PAXLOVID QL (22 EA per 180 days)
    PAXLOVID (300/100)PAXLOVID QL (60 EA per 180 days)
    BIKTARVYTier 5 QL (30 EA per 30 days)
    ISENTRESS HDTier 5 QL (60 EA per 30 days)
    VIREAD ORAL POWDERTier 5 QL (240 GM per 30 days)
    Supply and device entries with PAmixed
    bd pen needlePA required (multiple pen needle SKUs listed with PA)
    assure id insulin safety syrassure id insulin safety syr — Tier 1; Requirements/Limits = PA
    Formulary tier legendmixed
    No codes listed
    Quantity limits examplesmixed
    300 ML per 30 daysExample QL for certain oral solutions (XELJANZ ORAL SOLUTION listed with QL 300 ML per 30 days)
    60 EA per 30 daysQL for XELJANZ ORAL TABLET
    30 EA per 30 daysQL for XELJANZ XR ORAL TABLET XR 11 MG
    8 ML per 28 daysQL for COSENTYX (300 mg dose) and COSENTYX UNOREADY
    2 ML per 28 daysQL for COSENTYX 75 mg prefilled syringe
    3.42 ML per 30 daysQL for DUPIXENT 200 mg formulations
    8 ML per 30 daysQL for DUPIXENT 300 mg formulations
    1.34 ML per 30 daysQL for DUPIXENT 100 mg prefilled syringe
    180 ML per 30 daysQL for RINVOQ LQ
    30 EA per 30 daysQL for RINVOQ 15/30 mg tablets
    Testosterone topical quantity limitsmixed
    150 GM per 30 daysQL for testosterone transdermal gel (1.62% formulation listed)
    300 GM per 30 daysQL for certain testosterone transdermal gel (1% formulation)
    180 ML per 30 daysQL for testosterone transdermal solution
    NDC/CPT/HCPCS not listed in excerptmixed
    No codes listed
    Example quantity limits
    Fentanyl transdermal patch (72 hour)QL 10 EA per 30 days
    Hydromorphone ER oral tabletQL 60 EA per 30 days
    Methadone HCl oral solution 10 mg/5 mLQL 600 ML per 30 days
    DIFICID oral suspension QL
    DIFICID (fidaxomicin) oral suspension — reconstitutedQL 136 ML per 10 days
    Requirement noteListed with Step Therapy (ST); QL applies per 10-day course
    DIFICID oral tablet QL
    DIFICID (fidaxomicin) oral tabletQL 20 EA per 10 days
    Requirement noteListed with Step Therapy (ST); QL applies per 10-day course
    brivaracetam oral tablet QL
    Brivaracetam (oral tablet)QL 60 EA per 30 days
    Tier/requirementTier 5; Requirements/Limits = PA; QL applies
    Related formulationBrivaracetam oral solution has a separate QL (600 ML per 30 days)
    brivaracetam oral solution QL
    Brivaracetam (oral solution)QL 600 ML per 30 days
    Tier/requirementTier 5; Requirements/Limits = PA; QL applies
    XCOPRI QL examples
    XCOPRI (various strengths) — therapy packs/tabletsQL typically 56 EA per 28/30 days (pack-dependent); some packs QL 28 EA per 28 days or 60 EA per 30 days by strength
    Requirement noteTier 5; Requirements/Limits = PA; QL varies by strength and pack configuration
    Quantity Limits examples (memantine, AUVELITY, EXXUA)
    Memantine HCl (oral tablet)QL 49 EA per 28 days
    AUVELITYQL 60 EA per 30 days; Requirements/Limits = PA; NE
    EXXUARequirements/Limits = PA; QL 30 EA per 30 days
    Quantity limits examples — various per-drug QL values
    Examples across entriesMultiple QLs shown (examples include 240 EA per 30 days; 63 EA per 28 days; 30 EA per 30 days; 336 EA per 28 days; 540 ML per 30 days)
    ContextQL values vary by drug class (oncology, antivirals, specialty agents) and are listed with PA where applicable
    ActionRefer to specific drug entry for exact QL and PA requirements
    Quantity limits examples (examples up to 336 EA per period)
    High QL examplesSome products have QLs up to 336 EA per period (e.g., ROZLYTREK oral packet QL 336 EA per 28 days); other oncology entries show QLs like 240–840 EA per period
    Example drugsROZLYTREK, TAFINLAR oral soluble tablet, LIVTENCITY — see individual entries for per-period QL
    Quantity limits examples (30/60/240 GM examples)
    Mixed-unit QL examplesExamples include 30 EA per 30 days; 60 EA per 30 days; 240 GM per 30 days; 40 EA per 180 days; 22 EA per 180 days; 3 ML per 28 days
    NoteUnits vary by formulation (EA, GM, ML) — check the drug entry for unit and period
    Quantity limits examples (60 EA/30 ML/120 EA examples)
    Examples (EA/ML)QL examples include 60 EA per 30 days; 30 ML per 30 days; 120 EA per 30 days for specific products
    ContextThese QLs apply across CNS and movement-disorder products (e.g., tetrabenazine, RADICAVA ORS) and others
    QL examples (8 ML/3.42 ML/300 ML examples)
    Biologics/large-volume QLsExamples include 8 ML per 28 days (COSENTYX 300 mg), 3.42 ML per 30 days (DUPIXENT 200 mg), 300 ML per 30 days (XELJANZ oral solution)
    ApplicationQLs for biologics are expressed in mL per 28/30 days depending on strength; PA typically applies
    Quantity limits examples (0.5 ML/60 EA/1 EA per periods)
    Small-volume ophthalmic and injectablesExamples: 0.5 ML per 28 days (SELARSDI); 60 EA per 30 days (RESTASIS each); 1 EA per 365 days (SUNLENCA packs) — verify per-entry period
    Ophthalmic noteMany ophthalmics list ML-based QLs (e.g., OXERVATE 28 ML per 30 days; CYSTADROPS 20 ML per 30 days)

    Prescriber Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Requirement

    Prior Authorization Required — Prescribers must obtain prior authorization (PA) from Priority Health Medicare when PA is indicated for a drug. If PA is not obtained before dispensing, the plan may deny coverage for the claim. PA requirements are shown next to individual drugs in the formulary ("PA").

    • PA shown next to drugs in formulary entries (see specialty and high-cost listings).
    • Failure to obtain PA may result in non-coverage or claim denial.
    Prior Authorization

    Prior Authorization — select specialty/high‑cost drugs

    Prior authorization is required for select specialty and high-cost drugs. Many Tier 5 (specialty) products, oral oncology agents, biologics, and other high-cost therapies are designated PA and often have an accompanying quantity limit (QL) or other flag (HI, LA, B/D). Examples include ARIKAYCE, colistimethate sodium, XIFAXAN, and numerous oral oncology agents.

    • Examples: colistimethate sodium (PA; HI), XIFAXAN 200 mg & 550 mg (PA; QL), many oral oncology agents listed with PA and QL.
    • Tier 5 (specialty) drugs are typically 30-day supply only and frequently require PA.
    Prior Authorization

    Prior Authorization required for select specialty agents

    Prior authorization is required for many specialty agents (Tier 5) and select high‑cost non‑specialty products. These PA requirements are enforced at the point of fill and are often paired with quantity limits (QL) and other routing flags (HI = Home Infusion, B/D = Part B vs Part D, LA = Limited Availability).

    • Tier 5 examples with PA: BRIVIACT, EPIDIOLEX, XCOPRI, AUVELITY, EXXUA, ZURZUVAE.
    • Home infusion and Part B vs D flags may change documentation or approval routing.
    Prior Authorization

    Prior authorization required for listed specialty and named agents

    Prior authorization is required for listed specialty and named agents throughout the formulary. Many biologics, immunomodulators, and specialty injectable or infused products show PA with specific QL values.

    • Examples: DUPIXENT, SKYRIZI, ustekinumab, adalimumab biosimilars — all flagged PA; QL varies by product.
    • Some specialty products also carry LA (limited availability) or require home infusion (HI).
    Prior Authorization

    Prior authorization for specialty drugs

    Prior authorization applies broadly to specialty drugs; many oral oncology agents, advanced therapies, and specialty oral/IV products require prior approval before coverage will be granted.

    • Oral oncology examples with PA and QL: VITRAKVI, VERZENIO, VENCLEXTA, etc.
    • Check formulary entries for PA and QL indications before prescribing/dispensing.
    Prior Authorization

    Prior Authorization Required — check formulary entries

    Prior authorization is indicated next to individual drug entries where required. Review the formulary entry for the PA designation and any associated quantity limits (QL), step therapy (ST), home infusion (HI), Part B vs D (B/D) notes, or limited availability (LA) flags.

    • PA notation appears in the Requirements/Limits column for each drug that requires it.
    • Other flags (QL, ST, HI, B/D, LA, NE) modify how the drug is routed or documented.
    Prior Authorization

    Prior authorization required for specific specialty drugs

    Prior authorization is required for specific specialty drugs across therapeutic areas; several high‑cost ophthalmic, pulmonary, and biologic agents are listed with PA and QL.

    • Ophthalmic examples: OXERVATE, CYSTADROPS, CYSTARAN, XDEMVY — PA; QL specified per product.
    • Pulmonary specialty examples: ADEMPAS, OPSUMIT, OFEV, pirfenidone — PA; QL and sometimes LA flags.
    Denial Risk

    Prior authorization denial risk

    Prior authorization denial risk — prescriptions submitted without required PA, exceeding quantity limits, or not meeting step therapy/staging requirements may be denied. Prescribers and providers should confirm PA and QL before dispensing to avoid denials.

    • Denials can be triggered by missing PA, exceeding QL, or failure to complete ST requirements.
    • Tier 5 specialty drugs commonly trigger PA/QL denials if documentation is incomplete.
    Note

    Market withdrawal / removed drug

    Market withdrawal / removed drug — Priority Health Medicare may immediately remove a drug from the formulary if the manufacturer withdraws it from sale or the FDA withdraws approval for safety or effectiveness reasons. Members will be notified, and a transitional supply or exception process may be available.

    • If a drug is removed, affected members will be notified and may receive a temporary supply or instructions to request an exception.
    • Other formulary changes (generic entry, biosimilar placement, new restrictions) may be implemented with advance notice.
    Prior Authorization

    PA / QL for topical lidocaine

    Prior authorization and quantity limits for topical lidocaine — certain topical lidocaine products (patches and kits) require PA and have QL restrictions. Observe the PA/QL flags when prescribing or dispensing.

    • Lidocaine external patch 5% and LIDOCAN products: Requirements/Limits = PA; QL (90 EA per 30 days).
    • Similar topical lidocaine formulations may have PA and QL—check formulary.
    Prior Authorization

    PA / HI requirements for select specialty or IV agents

    PA and Home Infusion (HI) requirements — select IV and infused antibiotics and specialty agents require PA and may be routed through home infusion or specialty pharmacy programs. These flags affect coverage determination and documentation routing.

    • Examples: colistimethate sodium (PA; HI), daptomycin (Tier 5; HI), cefazolin and cefepime IV forms flagged HI.
    • Home infusion designation typically requires additional documentation and may affect benefit administration.
    Step Therapy

    Step therapy / quantity limit denials

    Step therapy and quantity limit denials — Failure to satisfy step therapy (ST) requirements or dispensing quantities beyond specified quantity limits (QL) can lead to claim denials. Step therapy may require trying and failing a preferred agent before coverage for an alternative.

    • DIFICID entries show ST; QL violations may result in denials.
    • Paliperidone ER and selected ophthalmic anti-inflammatories (difluprednate, loteprednol) are examples where ST may apply.
    Denial Risk

    Prior authorization denials for specialty drugs

    Prior authorization denials for specialty drugs — Many Tier 5 specialty drugs carry PA and QL requirements; incomplete or missing documentation for these products commonly results in denial of coverage.

    • Examples: BRIVIACT, EPIDIOLEX, XCOPRI, AUVELITY — all Tier 5 with PA; ensure documentation supports medical necessity.
    • Specialty denials often require prescriber appeal or submission of supporting clinical records.
    Prior Authorization

    PA and QL required for many Tier 5 drugs

    PA and QL are required for many Tier 5 drugs — Tier 5 (specialty) items are frequently subject to prior authorization, quantity limits, and 30‑day supply restrictions. Check each Tier 5 entry before prescribing.

    • Tier 5 drugs are noted as 30-day supply only; PA and QL values are provided per product.
    • Examples include many oncology, neurologic, and biologic specialty therapies.
    Prior Authorization

    PA required for many specialty drugs

    PA required for many specialty drugs across therapeutic classes — review formulary entries for PA, QL, ST, HI, and other flags prior to prescribing or dispensing; these indicators determine coverage and necessary documentation.

    • Cardiology, metabolic, and specialty endocrine agents (REPATHA, REDEMPLO, TRYNGOLZA) show PA; QL specified where applicable.
    • Oncology and rare disease therapies commonly require PA and have strict QL enforcement.
    Denial Risk

    Quantity limit exceedance

    Quantity limit exceedance — Prescriptions exceeding the formulary QL will likely be denied or require prior authorization/exception. Pharmacies and prescribers must observe QL limits at dispensing and claims submission.

    • QL examples: XARELTO 10 mg (30 tablets per 30 days), many product-specific QLs listed in formulary entries.
    • Exceeding QL may trigger a PA requirement or denial.
    Denial Risk

    Denial triggers from formulary flags

    Denial triggers from formulary flags — Coverage denials can be triggered by PA, ED (excluded drugs), QL, ST, B/D routing differences, HI, and LA flags. Confirm the applicable flags and required documentation before filling.

    • Common flags: PA (Prior Authorization), QL (Quantity Limits), ST (Step Therapy), HI (Home Infusion), B/D (Part B vs Part D), LA (Limited Availability), ED (Excluded Drug).
    • Each flag carries operational implications for coverage and documentation.
    Prior Authorization

    PA / QL triggers for specialty drugs

    PA/QL triggers for specialty drugs — Many specialty biologics, injectables, and oral specialty agents list both PA and QL; these triggers require prescriber-submitted documentation at the time of prior authorization request and may require ongoing authorization for refills.

    • REPATHA, REPATHA Pushtronex, and similar products: PA with specific ML QLs per 28–30 days.
    • Specialty injectables frequently require both initial PA and periodic reassessment for continuation.
    Prior Authorization

    Prior authorization required for specified products

    Prior authorization required for specified products — Many individual products across classes are explicitly listed with PA in the formulary. Prescribers should verify the PA requirement and any associated QL before prescribing.

    • Examples: AUSTEDO, EVRYSDI, NUEDEXTA, RADICAVA, tetrabenazine forms — PA and often QL.
    • Check therapeutic class sections for product-level PA entries.
    Prior Authorization

    FASENRA PA / QL

    FASENRA PA/QL — FASENRA prefilled syringe is subject to prior authorization and has a quantity limit noted in the formulary.

    • FASENRA prefilled syringe 10 mg/0.5 mL: Requirements/Limits = PA; QL (0.5 ML per 30 days).
    Prior Authorization

    PA and QL on testosterone topicals and insulin supplies

    PA and QL on testosterone topicals — Transdermal testosterone gels, solutions, and related supplies are subject to prior authorization and quantity limits. Insulin supplies and pen needles also require PA.

    • Testosterone transdermal gel products: Requirements/Limits = PA; QL values vary (examples: 150 GM/30 days, 300 GM/30 days, 37.5 GM/30 days).
    • Insulin supplies and pen needles listed with PA (assure id insulin safety syringes, BD pen needles, etc.).
    Prior Authorization

    PA / QL required for listed specialty ophthalmic agents

    PA/QL required for listed specialty ophthalmic agents — Several specialty ophthalmic products require prior authorization and have specific quantity limits; observe these flags when prescribing or dispensing ophthalmic specialty drugs.

    • Examples: OXERVATE (PA; QL 28 mL/30 days), CYSTADROPS (PA; QL 20 mL/30 days), XDEMVY (PA; QL 10 mL/180 days).
    • Some ophthalmic anti-inflammatories and steroid agents may also be ST-flagged (difluprednate, loteprednol).
    Prior Authorization

    PA / QL for pulmonary specialty agents

    PA/QL for pulmonary specialty agents — Pulmonary hypertension and interstitial lung disease therapies are commonly PA‑restricted with QLs and sometimes limited availability. Confirm PA before initiating therapy.

    • Examples: ADEMPAS, OPSUMIT, ambrisentan, bosentan — Requirements/Limits = PA; QL and LA flags present for some products.
    • Prescribers should document diagnosis and prior therapies when requesting PA for pulmonary agents.
    Documentation Required

    Prescriber supporting statement

    Prescriber supporting statement — When requesting an exception or prior authorization, the prescriber must provide a supporting statement explaining the medical rationale for the request. For tiering or formulary exceptions, Priority Health Medicare generally decides within 72 hours of receiving the prescriber's supporting statement (24 hours for expedited requests when clinically warranted).

    • Prescriber's explanation should describe why alternative formulary drugs are not effective or would cause adverse effects.
    • Expedited (fast) decisions are available when waiting could seriously harm the member; decision timeline 24 hours after receiving supporting statement if expedited.
    Documentation Required

    Supporting documentation for requirement codes

    Supporting documentation for requirement codes — Providers must supply documentation when submitting PA, QL, ST, HI, LA, B/D, or other flagged requests. Documentation should include clinical indication, prior therapies tried (for ST), dosing, and rationale for exceeding QL if applicable.

    • ST requests should include prior therapy history showing failure, intolerance, or contraindication to preferred agents.
    • B/D (Part B vs Part D) entries may require documentation describing the use and setting of the drug to determine correct benefit routing.
    Documentation Required

    Formulary legend and documentation expectations

    Formulary legend and documentation expectations — The formulary legend defines abbreviations (PA, QL, ST, HI, B/D, LA, NE, ED). Refer to the legend to interpret flags and follow the documentation expectations described in the formulary and on the plan website when submitting PA or exception requests.

    • Legend examples: PA = Prior Authorization, QL = Quantity Limit, ST = Step Therapy, HI = Home Infusion, B/D = Part B vs Part D, LA = Limited Availability, NE = No Express Scripts.
    • Tier definitions: T1–T5 with T5 = Specialty (30-day supply only).
    Documentation Required

    Documentation for prior authorization

    Documentation for PA — When PA is required, submit clinical documentation that supports medical necessity (diagnosis, prior treatments, dosing, expected duration). For Part B vs D determinations, include setting and use details as requested.

    • Include prescriber's supporting statement and relevant clinical notes to expedite a PA decision.
    • For B/D flagged drugs, indicate whether administration is in an outpatient/medical setting (Part B) or for outpatient pharmacy dispensing (Part D).
    Documentation Required

    PA documentation for insulin supplies

    PA documentation for insulin supplies and pen needles — Insulin delivery devices and pen needles listed in the formulary require prior authorization. Provide clinical justification and device necessity when submitting PA requests.

    • Examples: assure id insulin safety syringes, BD pen needles, and other listed insulin supplies carry PA requirements.
    • Supplies often require documentation of diabetes diagnosis and intended use.
    Billing Rule

    Observe QL when dispensing

    Observe quantity limits (QL) when dispensing — Pharmacies must adhere to the QL specified in each formulary entry at dispensing and claims adjudication. Dispensing beyond the QL may deny coverage or require a prior authorization/exception.

    • QLs are enforced per period listed (e.g., per 30 days, per 28 days, per 365 days) — follow the period indicated for each product.
    • Examples: many psychiatric and cardiovascular agents have explicit per‑30‑day QLs.
    Billing Rule

    Quantity limit adherence

    Quantity limit adherence — Providers and pharmacies must ensure prescribed quantities align with formulary QLs or obtain a PA/exception. Exceeding QL without authorization can trigger denials and may require appeals.

    • Where QL is specified (EA, ML, GM), ensure the unit and period match the formulary entry before dispensing.
    • Requests to exceed QL should include justification and supporting clinical documentation.
    Documentation Required

    PA / QL documentation requirement

    PA/QL documentation requirement — For drugs marked PA and/or QL, the plan requires submission of supporting clinical documentation with the authorization request. This may include diagnosis codes, prior therapy history, lab results, or other evidence of medical necessity.

    • Specialty products often require more extensive documentation and may need ongoing authorization for refills.
    • Home infusion or Part B routed drugs require documentation specific to setting and administration.
    Documentation Required

    PA documentation guidance

    PA documentation — Provide concise, targeted clinical information with PA requests to avoid delays. Include prior medication trials (for ST), reason for selecting non‑formulary therapy (for exceptions), and anticipated duration of therapy.

    • For expedited requests, ensure prescriber's statement clearly documents the clinical urgency to meet the 24‑hour review timeline.
    • Attach relevant office notes, labs, or specialty consults as needed.
    Documentation Required

    Documentation and routing note

    Documentation and routing note — Use the formulary legend and product flags to determine correct benefit routing and required documentation: B/D (Part B vs Part D), HI (Home Infusion), NE (No Express Scripts), LA (Limited Availability). Submitting correct supporting information prevents miscoding and routing delays.

    • B/D items may require physician attestation of setting/use.
    • HI items may be coordinated through home infusion providers and require separate documentation.
    Note

    Formulary requirement types

    Formulary requirement types — The formulary uses several requirement codes (PA, QL, ST, HI, B/D, ED, LA, NE). Providers must consult the legend and the individual drug entry to determine what is required and submit the appropriate documentation for coverage consideration.

    • PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; HI = Home Infusion; B/D = Part B vs Part D; ED = Excluded Drug; LA = Limited Availability; NE = No Express Scripts.
    • Tier 5 designation indicates specialty tier and 30‑day supply restrictions.
    Step Therapy

    Step therapy presence and note

    Step therapy presence noted — Step therapy (ST) appears throughout the formulary legend and in multiple drug entries; where ST is indicated, members must try specified first‑line drugs before coverage of alternatives is considered. Specific step requirements are shown on product entries or in the plan's prior authorization/step therapy policy documents online.

    • ST is listed in the legend and appears on product-level entries (e.g., DIFICID, FETZIMA, paliperidone ER, calcitriol external).
    • Detailed ST steps and requirements are available in the plan's PA/ST documents on the website or by request.
    Step Therapy

    Step Therapy Requirements

    Step therapy requirements — Where 'ST' is indicated, the formulary or prior authorization policy will specify required trials or criteria. Prescribers should document prior medication trials, reasons for failure or intolerance, and any contraindications when requesting an override or exception.

    • Examples with ST: FETZIMA (ST; QL), paliperidone ER (ST; QL), calcitriol external (ST).
    • Requests to waive ST should include documentation of prior treatment failure, intolerance, or clinical rationale.
    Step Therapy

    Step therapy notation and ophthalmic examples

    Step therapy mentioned and notation — The formulary legend includes ST and individual product entries include ST notation where applicable. For certain ophthalmic anti‑inflammatories (difluprednate, loteprednol), ST is applied.

    • Ophthalmic ST examples: difluprednate (ST), loteprednol (ST).
    • Refer to product entry and the plan's ST documentation for the specific required trial sequence.

    Step Therapy Rules and References

    Step therapy general rule
    Member must try required alternative(s) (specified first-line agents) before Priority Health Medicare will cover a different drug for the same condition; if the preferred agent fails or is contraindicated, the plan will then cover the alternative.
    Where ST appliesPrescriber documentation
    Step therapy applies to drugs where 'ST' is indicated in the formulary entry (see formulary listings).
    Prescriber must document trial and failure of the required prior agent(s) or document a contraindication to the required agent(s) when requesting coverage of the non-preferred drug.
    ST in legendPer‑drug rules in excerpt
    {"text":"'ST' (Step Therapy) is defined in the formulary legend/abbreviations as a possible requirement.','status": ""}
    The provided excerpt includes the ST abbreviation in the legend but does not include full, explicit per‑drug step therapy step edits or step sequences for most agents.
    ProductST requirement
    DIFICID oral suspension (reconstituted) — Tier 5; Requirements/Limits = ST; QL (136 ML per 10 days)
    DIFICID oral tablet — Tier 5; Requirements/Limits = ST; QL (20 EA per 10 days)
    AgentST / prescriber expectation
    FETZIMA — Requirements/Limits = ST; QL (30 EA per 30 days); prescriber expected to document prior trial/failure or contraindication to required agent(s)
    TRINTELLIX (referenced among branded antidepressants) — step therapy indicated for select branded antidepressants; prescriber must document trials as required by ST rules
    Vilazodone HCl — Requirements/Limits = ST; QL (30 EA per 30 days); prescriber expected to document prior trial/failure or contraindication
    ST definedDrug-specific ST steps present?
    ST (Step Therapy) is defined in the formulary abbreviations as requiring trial of preferred agents first.
    No detailed, drug-specific step therapy step sequences or step edits are provided in these excerpted chunks; check full formulary entries for specifics.
    Formulary entryST flag / implication
    Paliperidone ER 1.5 mg / 3 mg / 9 mg — Requirements/Limits = ST; QL (30 EA per 30 days)
    Paliperidone ER 6 mg — Requirements/Limits = ST; QL (60 EA per 30 days)
    ST referencedSpecific rules in excerpt
    Formulary entries and legend reference 'ST' (Step Therapy) as a possible requirement for some products.
    This excerpt does not include the specific step therapy rules or required prior agents for those products; refer to the complete formulary or utilization management guides for details.
    Legend lists STPer‑drug step edits present?
    The formulary legend lists ST among abbreviations (ST = Step Therapy).
    No specific step edits for individual drugs are included in the provided excerpt of the formulary (legend only).
    ProductST indicated
    Calcitriol external — Drug Tiers = 4; Requirements/Limits = ST (step therapy may apply)
    ST referenceDetails in excerpt
    Step Therapy (ST) is included in the formulary abbreviation key alongside PA and QL.
    Specific step therapy rules for most drugs are not detailed in these excerpted chunks; consult the full formulary entries or PA/ST policy for drug‑level steps.
    Formulary keyST mechanism present?
    Formulary key lists requirement abbreviations including ST, with explanatory note that Tier 5 drugs are 30‑day supply only.
    While the key references step therapy as a mechanism, the excerpt does not list the actual step edits (specific required prior agents) here.
    Ophthalmic productST requirement
    Travoprost (BAK‑free) — Drug Tiers = 3; Requirements/Limits = ST (step therapy required per formulary listing)
    Ophthalmic anti‑inflammatoryST requirement
    Difluprednate — Drug Tiers = 3; Requirements/Limits = ST (step therapy must be followed per formulary listing)
    Loteprednol etabonate (gel & suspension) — Drug Tiers = 3; Requirements/Limits = ST (step therapy must be followed per formulary listing)

    Quantity Limits (QL) by Drug / Examples

    Selected QL examples
    DIFICID suspensionQL 136 ML per 10 days
    Brivaracetam solutionQL 600 ML per 30 days
    XCOPRI therapy packs/tabletsQL varies by pack: commonly 56 EA per 28/30 days or 28 EA per 28 days depending on pack
    diclofenac sodium external solution 1.5% QL
    Diclofenac sodium external solution 1.5%QL 750 ML per 30 days
    ContextListed under analgesics with QL in mL per 30 days
    fentanyl transdermal patch 72 hour QL
    Fentanyl transdermal patch (72 hour)QL 10 EA per 30 days
    TierSee formulary entry for tier and PA flags
    hydromorphone ER oral tablet QL
    Hydromorphone ER oral tabletQL 60 EA per 30 days
    Related formsOral liquid and injection forms have separate QLs listed
    methadone oral solution QL
    Methadone HCl oral solution 10 mg/5 mLQL 600 ML per 30 days
    Other strengthsMethadone 5 mg/5 mL QL 1200 ML per 30 days; tablets have EA-based QLs
    morphine sulfate ER 100 mg QL
    Morphine sulfate ER oral tablet 100 mgQL 60 EA per 30 days
    Other morphine ER strengthsOther ER strengths have separate QLs (e.g., 120 EA per 30 days for some strengths)
    vancomycin HCl oral capsule 125 mg QL
    Vancomycin HCl oral capsule 125 mgQL 80 EA per 30 days
    Other strengths250 mg QL 160 EA per 30 days; oral solution entries listed separately
    DIFICID oral suspension reconstituted QL
    DIFICID oral suspension (reconstituted)QL 136 ML per 10 days
    Formulation noteListed with Step Therapy (ST); QL tied to 10-day course typical for C. difficile treatment
    DIFICID oral tablet QL
    DIFICID oral tabletQL 20 EA per 10 days
    Formulation noteListed with Step Therapy (ST); QL tied to 10-day course
    brivaracetam oral solution QL
    Brivaracetam oral solutionQL 600 ML per 30 days
    RequirementTier 5; PA required
    brivaracetam oral tablet QL
    Brivaracetam oral tabletQL 60 EA per 30 days
    RequirementTier 5; PA required
    XCOPRI various strengths QL
    XCOPRI (various strengths)Common QL 56 EA per 28/30 days (pack-dependent); some formulations QL 28 EA per 28 days or 60 EA per 30 days
    RequirementPA; QL varies by strength/pack
    memantine hcl QL
    Memantine HCl (oral tablet)QL 49 EA per 28 days
    ContextListed under dementia agents with EA per 28-day QL
    AUVELITY QL
    AUVELITYQL 60 EA per 30 days; Requirements/Limits = PA; NE
    NoteNE indicates No Express Scripts for home delivery in some entries
    FETZIMA QL
    FETZIMAQL 30 EA per 30 days; Requirements/Limits = ST
    FormulationIncludes titration pack entries with same QL
    AIMOVIG QL
    AIMOVIG (CGRP antagonist)QL 1 ML per 30 days; Requirements/Limits = PA
    Related agentsEMGALITY, NURTEC have distinct QLs and PA flags
    IWILFIN QL
    IWILFINQL 240 EA per 30 days
    ContextListed as Tier 5 with PA; large QL example
    KISQALI (200 mg) QL example
    KISQALI (200 mg) — exampleQL 49 EA per 28 days (some KISQALI dose listings show 63 EA per 28 days depending on dose)
    NoteKISQALI QL varies by dose; check specific dose entry
    XPOVIO therapy pack example QL
    XPOVIO therapy pack examplesQL examples include 8 EA per 28 days (varies by pack/dosing schedule)
    RequirementPA applies to many therapy-pack oncology agents
    KISQALI various doses QL
    KISQALI (various doses)Some dose listings show QL 63 EA per 28 days (per-entry variation by strength)
    ContextOncology QLs vary by dose; PA commonly applies
    ROZLYTREK and TAFINLAR QL examples
    ROZLYTREK oral packetQL 336 EA per 28 days
    TAFINLAR oral soluble tabletQL 840 EA per 28 days
    Various QL examples (mixed)
    Mixed QL summaryExamples include: 60 EA per 30 days; 90 EA per 30 days; 300 ML per 30 days; 336 EA per 28 days; 540 ML per 30 days
    InstructionRefer to individual entries for PA/ST flags and exact supply periods
    Various QL examples across entries
    Examples by unit & period30 EA/30 days; 60 EA/30 days; 300 EA/30 days; 240 GM/30 days; 40 EA/180 days; 22 EA/180 days; 3 ML/28 days
    NoteUnits and periods depend on formulation and drug; check specific line-item
    amlodipine-besylate-valsartan QL
    Amlodipine-besylate-valsartan (certain strengths)QL varies by strength: 30 EA per 30 days, 60 EA per 30 days, or 120 EA per 30 days depending on strength
    ActionDispense per strength-specific QL
    ENTRESTO oral capsule sprinkle QL
    ENTRESTO oral capsule sprinkleQL 240 EA per 30 days
    TierTier 3 entry with QL specified
    sacubitril-valsartan QL
    Sacubitril-valsartan (selected strengths)QL 90 EA per 30 days or 60 EA per 30 days depending on strength
    InstructionConfirm strength-specific QL when dispensing
    REDEMPLO / TRYNGOLZA QL examples
    REDEMPLOQL 0.5 ML per 84 days
    TRYNGOLZAQL 0.8 ML per 30 days
    REPATHA product QLs
    REPATHA productsQL examples: 2 ML per 28 days; REPATHA PUSHTRONEX 3.5 ML per 30 days; SURECLICK 2 ML per 28 days
    RequirementPA applies to REPATHA entries
    atorvastatin QL examples
    Atorvastatin (various strengths)QL varies by strength (examples: 240/120/60/30 EA per 30 days depending on strength)
    DispensingObserve strength-specific QL when dispensing
    dextroamphetamine & methylphenidate QLs
    Dextroamphetamine sulfate (tablet/capsule)QL 60 EA per 30 days; some strengths QL 120 EA per 30 days
    Methylphenidate oral solutionQL 1500 ML per 30 days (10 mg/5 mL solution) — large-volume example
    AUSTEDO, duloxetine, MS injectables QLs
    AUSTEDO oral tablet 12 mg/9 mgPA; QL 120 EA per 30 days
    Duloxetine HCl 20 mgQL 180 EA per 30 days
    AVONEX and MS injectablesPA; QL examples include 4 EA per 28 days, 15 EA per 30 days
    tolvaptan, FASENRA, LOKELMA QLs
    Tolvaptan (tablets)QL 120 EA per 30 days; Therapy pack QL 56 EA per 28 days; Requirements/Limits = PA
    FASENRA prefilled syringeQL 0.5 ML per 30 days; Requirements/Limits = PA
    LOKELMA oral packet 10 GMQL 90 EA per 30 days
    OTEZLA, OXERVATE, CYSTADROPS QLs
    OTEZLA oral tablet 20 mgQL 60 EA per 30 days; Requirements/Limits = PA
    OXERVATE (ophthalmic)QL 28 ML per 30 days; Requirements/Limits = PA
    CYSTADROPSQL 20 ML per 30 days
    Restasis / Cystaran QLs
    RESTASIS (each)QL 60 EA per 30 days
    RESTASIS MULTIDOSEQL 5.5 ML per 30 days
    CYSTARANQL 60 ML per 28 days
    SODIUM OXYBATE QL
    Sodium oxybateQL 540 ML per 30 days; Requirements/Limits = PA; LA
    NoteHigh-volume liquid QL example — check LA (limited availability) status
    epinephrine auto-injector QL
    Epinephrine auto-injectorQL 4 EA per 30 days
    ContextCommon emergency-medication QL for auto-injectors
    TRIKAFTA therapy pack QL
    TRIKAFTA oral tablet therapy packQL 84 EA per 28 days
    ContextCystic fibrosis therapy pack QL example

    Home Infusion, Part B vs Part D, and Benefit Routing

    Note
    Note
    Note
    Note
    Note

    Abbreviations, Tier Legend, and Definitions

    Policy Background and Scope

    The formulary states it covers prescription drugs and biological products (including biosimilars) for Priority Health Medicare members. The background explains that biological products and biosimilars are treated as part of the formulary drug list and subject to the same tiering and utilization controls shown in the document.